Greenleaf Trust Sells 1,789 Shares of Baxter International Inc. (NYSE:BAX)

Greenleaf Trust decreased its holdings in shares of Baxter International Inc. (NYSE:BAX) by 13.1% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 11,860 shares of the medical instruments supplier’s stock after selling 1,789 shares during the period. Greenleaf Trust’s holdings in Baxter International were worth $459,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Livforsakringsbolaget Skandia Omsesidigt raised its position in shares of Baxter International by 76.6% during the 4th quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 1,439 shares of the medical instruments supplier’s stock valued at $56,000 after acquiring an additional 624 shares during the last quarter. ORG Partners LLC increased its position in shares of Baxter International by 3,748.2% in the 4th quarter. ORG Partners LLC now owns 2,155 shares of the medical instruments supplier’s stock valued at $83,000 after buying an additional 2,099 shares in the last quarter. CKW Financial Group bought a new stake in shares of Baxter International in the 4th quarter valued at $43,000. Impax Asset Management Group plc increased its position in shares of Baxter International by 46.8% in the 4th quarter. Impax Asset Management Group plc now owns 1,170,655 shares of the medical instruments supplier’s stock valued at $45,258,000 after buying an additional 373,409 shares in the last quarter. Finally, Tobam increased its position in shares of Baxter International by 1.1% in the 4th quarter. Tobam now owns 344,375 shares of the medical instruments supplier’s stock valued at $13,314,000 after buying an additional 3,865 shares in the last quarter. Institutional investors own 90.19% of the company’s stock.

Baxter International Price Performance

Shares of NYSE BAX opened at $41.03 on Wednesday. The company has a fifty day moving average price of $41.83 and a 200 day moving average price of $38.49. Baxter International Inc. has a 1-year low of $31.01 and a 1-year high of $50.21. The company has a current ratio of 1.48, a quick ratio of 1.04 and a debt-to-equity ratio of 1.31. The firm has a market cap of $20.84 billion, a PE ratio of 7.86, a PEG ratio of 2.12 and a beta of 0.62.

Baxter International (NYSE:BAX) last posted its quarterly earnings data on Thursday, February 8th. The medical instruments supplier reported $0.88 EPS for the quarter, topping analysts’ consensus estimates of $0.86 by $0.02. Baxter International had a net margin of 17.77% and a return on equity of 19.49%. The company had revenue of $3.89 billion during the quarter, compared to the consensus estimate of $3.81 billion. During the same period in the prior year, the business posted $0.88 EPS. The company’s quarterly revenue was up 3.5% on a year-over-year basis. Research analysts predict that Baxter International Inc. will post 2.89 earnings per share for the current fiscal year.

Baxter International Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, April 1st. Stockholders of record on Friday, March 1st were paid a dividend of $0.29 per share. The ex-dividend date was Thursday, February 29th. This represents a $1.16 dividend on an annualized basis and a dividend yield of 2.83%. Baxter International’s dividend payout ratio is 22.22%.

Wall Street Analysts Forecast Growth

BAX has been the subject of a number of recent analyst reports. UBS Group lowered their price objective on shares of Baxter International from $40.00 to $36.00 and set a “neutral” rating for the company in a research report on Tuesday, February 6th. Barclays upped their price objective on shares of Baxter International from $52.00 to $54.00 and gave the company an “overweight” rating in a research report on Monday, February 12th. StockNews.com upgraded shares of Baxter International from a “hold” rating to a “buy” rating in a research report on Friday, January 19th. Citigroup upped their price objective on shares of Baxter International from $41.00 to $44.00 and gave the company a “neutral” rating in a research report on Wednesday, April 3rd. Finally, Bank of America upped their target price on shares of Baxter International from $42.00 to $45.00 and gave the stock a “neutral” rating in a research note on Tuesday, March 5th. Seven equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $46.30.

Baxter International Company Profile

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.